Company news

Processa Pharmaceuticals, Inc. news in 2023

Processa Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

December 18, 2023

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

December 12, 2023

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

October 31, 2023

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

August 7, 2023

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

May 17, 2023

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

March 29, 2023

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

March 16, 2023

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

February 20, 2023

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules

February 14, 2023

Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

February 9, 2023

Calls in 2023

Decks in 2023